{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reduced+Intensity+Conditioning+%28RIC%29+Allogenic+Transplant", "query": { "intervention": "Reduced Intensity Conditioning (RIC) Allogenic Transplant" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 45, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reduced+Intensity+Conditioning+%28RIC%29+Allogenic+Transplant&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T14:43:23.057Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01050855", "title": "Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Malignant Diseases", "Immunodeficiencies", "Hemoglobinopathies" ], "interventions": [ { "name": "Reduced-Intensity Conditioning", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "25 Years", "sex": "ALL", "summary": "6 Months to 25 Years" }, "enrollment_count": 56, "start_date": "2008-01", "completion_date": "2025-06", "has_results": true, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-09-26T14:43:23.057Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01050855" }, { "nct_id": "NCT01643668", "title": "Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Allogeneic Stem Cell Infusion", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2012-07", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2017-07-13", "last_synced_at": "2026-09-26T14:43:23.057Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01643668" }, { "nct_id": "NCT01339910", "title": "Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia, Myelocytic, Acute" ], "interventions": [ { "name": "Fludarabine and Busulfan", "type": "DRUG" }, { "name": "Fludarabine and Melphalan", "type": "DRUG" }, { "name": "Busulfan and Fludarabine", "type": "DRUG" }, { "name": "Busulfan and Cyclophosphamide", "type": "DRUG" }, { "name": "Cyclophosphamide and Total Body Irradiation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 272, "start_date": "2011-06", "completion_date": "2017-10-16", "has_results": true, "last_update_posted_date": "2023-01-04", "last_synced_at": "2026-09-26T14:43:23.057Z", "location_count": 32, "location_summary": "Phoenix, Arizona • La Jolla, California • Gainesville, Florida + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01339910" }, { "nct_id": "NCT03663933", "title": "Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoproliferative Disorders", "Autoimmune Lymphoproliferative", "Primary T-cell Immunodeficiency Disorders", "Immune System Diseases", "Common Variable Immunodeficiency" ], "interventions": [ { "name": "e-ATG", "type": "DRUG" }, { "name": "Immunosuppression Only Conditioning", "type": "PROCEDURE" }, { "name": "Reduced Intensity Conditioning", "type": "PROCEDURE" }, { "name": "GVHD Prophylaxis", "type": "DRUG" }, { "name": "Allogeneic HSC", "type": "PROCEDURE" }, { "name": "Bisulfan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "MMF", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Pentostatin", "type": "DRUG" }, { "name": "PFTs", "type": "DIAGNOSTIC_TEST" }, { "name": "DEXA", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone Marrow Aspirate & Biopsy", "type": "PROCEDURE" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "2D ECHO", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "PROCEDURE", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 71, "start_date": "2018-09-04", "completion_date": "2030-04-03", "has_results": true, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-09-26T14:43:23.057Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03663933" }, { "nct_id": "NCT00548717", "title": "Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft-vs-Host Disease" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2007-10", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2014-10-21", "last_synced_at": "2026-09-26T14:43:23.057Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00548717" }, { "nct_id": "NCT05298358", "title": "RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Sclerosis" ], "interventions": [ { "name": "RIC alloBMT w PTCy in refractory SSc", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1, "start_date": "2022-11-18", "completion_date": "2024-11-21", "has_results": false, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-09-26T14:43:23.057Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05298358" }, { "nct_id": "NCT03922724", "title": "Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral T-cell Lymphomas", "Lymphoproliferative Disorders", "Immune System Diseases" ], "interventions": [ { "name": "ATL-RIC", "type": "DRUG" }, { "name": "mRIC", "type": "DRUG" }, { "name": "allo HCT", "type": "PROCEDURE" }, { "name": "RIC", "type": "DRUG" }, { "name": "GVHD prophylaxis", "type": "DRUG" }, { "name": "IOC", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "12 Years to 120 Years" }, "enrollment_count": 91, "start_date": "2019-04-18", "completion_date": "2030-10-31", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-09-26T14:43:23.057Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03922724" }, { "nct_id": "NCT01343368", "title": "Preservation of Ovarian Function After Hematopoietic Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Non-Hodgkin Lymphoma", "Hodgkin Disease", "Acute Myeloid Leukemia", "Myeloproliferative Disorders" ], "interventions": [ { "name": "Leuprolide", "type": "DRUG" }, { "name": "hematopoietic cell transplant", "type": "BIOLOGICAL" }, { "name": "reduced intensity allogeneic HCT", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "FEMALE", "summary": "50 Years and older · Female only" }, "enrollment_count": 19, "start_date": "2011-07", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-09-26T14:43:23.057Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01343368" }, { "nct_id": "NCT05600101", "title": "Development and Piloting an Avatar-based Intervention to Support Patients Undergoing Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematopoietic Cell Transplantation" ], "interventions": [ { "name": "Care.Coach", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2022-12-06", "completion_date": "2023-05-16", "has_results": true, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-09-26T14:43:23.057Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05600101" }, { "nct_id": "NCT06803745", "title": "Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Leukemia", "Acute Lymphoblastic Lymphoma" ], "interventions": [ { "name": "200 cGy or 400 cGy total body irradiation (TBI)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 160, "start_date": "2025-03-27", "completion_date": "2030-09-30", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-09-26T14:43:23.057Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06803745" } ] }